The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much. However, there are ...

In a court filing on Monday, the Department of Health and Human Services fired back at Vertex Pharmaceuticals, standing by a directive that the biotech’s proposed fertility services program to go with ...

Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given its dominance in the cystic fibrosis treatment category and diversified pipeline, making a compelling case ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify its ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $520.00. Discover outperforming stocks and invest ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as ...